Moreover, using CD40- and FcγR-humanized C57BL/6J mice harbouring MB49 or UPPL1541 tumours, it was shown that the human anti-CD40 agonist antibody 2141-V11 caused reduced tumour size and that this effect was enhanced by cotreatment with IL-15 [37▪]. Here, FCGR2A is linked to neoplasm.